{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:56:40Z","timestamp":1790488600524,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Background and Aims<\/jats:title>\n            <jats:p>Patients with hepatitis C virus (HCV) and advanced fibrosis remain at risk of hepatocellular carcinoma (HCC) after sustained viral response (SVR) and need lifelong surveillance. Because HCC risk is not homogenous and may decrease with fibrosis regression, we aimed to identify patients with low HCC risk based on the prediction of noninvasive markers and its changes after SVR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results<\/jats:title>\n            <jats:p>This is a multicenter cohort study, including patients with HCV and compensated advanced fibrosis that achieved SVR after direct antivirals. Clinical and transient elastography (TE) data were registered at baseline, 1\u00a0year, and 3\u00a0years after the end of treatment (EOT). All patients underwent liver ultrasound scan every 6\u00a0months. Patients with clinical evaluation 1\u00a0year after EOT were eligible. Univariate and multivariate Cox regression analysis were performed, and predictive models were constructed. HCC occurrence rates were evaluated by Kaplan\u2010Meier. Nine hundred and ninety\u2010three patients were eligible (56% male; 44% female; median age 62\u00a0years), 35 developed HCC (3.9%), and the median follow\u2010up was 45\u00a0months (range 13\u201053). Baseline liver stiffness measurement (LSM) (HR 1.040; 95% CI 1.017\u20101.064), serum albumin (HR 0.400; 95% CI 0.174\u20100.923), 1\u2010year DeltaLSM (HR 0.993; 95% CI 0.987\u20100.998), and 1\u2010year FIB\u20104 score (HR 1.095; 95% CI 1.046\u20101.146) were independent factors associated with HCC. The TE\u2010based HCC risk model predicted 0% of HCC occurrence at 3\u00a0years in patients with score 0 (baseline LSM\u00a0\u2264\u00a017.3\u00a0kPa, albumin &gt;4.2\u00a0g\/dL, and 1\u2010year DeltaLSM\u00a0&gt;\u00a025.5%) versus 5.2% in patients with score 1\u20103 (Harrell\u2019s C 0.779; log\u2010rank 0.002). An alternative model with FIB\u20104 similarly predicted HCC risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A combination of baseline and dynamic changes in noninvasive markers may help to identify patients with a very low risk of HCC development after SVR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.31588","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T22:07:59Z","timestamp":1602022079000},"page":"1924-1934","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":86,"title":["A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus\u2013Advanced Fibrosis"],"prefix":"10.1097","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-0846","authenticated-orcid":false,"given":"Sonia","family":"Alonso L\u00f3pez","sequence":"first","affiliation":[{"name":"Liver Unit,Hospital General Universitario Gregorio Mara\u00f1\u00f3n,Madrid,Spain"},{"name":"Instituto De Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM),Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Manzano","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital Universitario 12 De Octubre,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gea","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital Universitario Ram\u00f3n y Cajal,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit,Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Maria","family":"Ahumada","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital General Universitario Gregorio Mara\u00f1\u00f3n,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Devesa","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit,Hospital Universitario Cl\u00ednico San Carlos,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Olveira","sequence":"additional","affiliation":[{"name":"Hepatology Unit,Hospital Universitario La Paz,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Arturo","family":"Polo","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit,Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital General Universitario Gregorio Mara\u00f1\u00f3n,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital Universitario 12 De Octubre,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos Ruiz","family":"Cobo","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital Universitario Ram\u00f3n y Cajal,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ray\u00f3n","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital General Universitario Gregorio Mara\u00f1\u00f3n,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Riado","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit,Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit,Hospital Universitario Cl\u00ednico San Carlos,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Us\u00f3n","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital General Universitario Gregorio Mara\u00f1\u00f3n,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Real","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit,Hospital Universitario La Princesa Madrid,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Rinc\u00f3n","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital General Universitario Gregorio Mara\u00f1\u00f3n,Madrid,Spain"},{"name":"Instituto De Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM),Madrid,Spain"},{"name":"Universidad Complutense de Madrid,Madrid,Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica En Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD),Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado M.","family":"Fern\u00e1ndez\u2010Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit,Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n,Madrid,Spain"},{"name":"Universidad Rey Juan Carlos Madrid,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Ba\u00f1ares","sequence":"additional","affiliation":[{"name":"Liver Unit,Hospital General Universitario Gregorio Mara\u00f1\u00f3n,Madrid,Spain"},{"name":"Instituto De Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM),Madrid,Spain"},{"name":"Universidad Complutense de Madrid,Madrid,Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica En Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD),Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"hep31588-bib-0001-20241017","first-page":"1688","article-title":"Sofosbuvir and velpatasvir for patients with HCV infection","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"hep31588-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep31588-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT\u2010450\/r\u2010ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep31588-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT\u2010450\/r\u2010ombitasvir and dasabuvir with ribavirin","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep31588-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY\u20103+)","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep31588-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon\u2010alpha is associated with improved outcome in HCV\u2010related cirrhosis: a retrospective study","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep31588-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/ajg.2010.294","article-title":"Peginterferon plus ribavirin and sustained virological response in HCV\u2010related cirrhosis: outcomes and factors predicting response","volume":"105","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"hep31588-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on treatment of Hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep31588-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","article-title":"AGA clinical practice update on interaction between oral direct\u2010acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep31588-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep31588-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis\u2010related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep31588-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","article-title":"Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival","volume":"142","year":"2005","journal-title":"Ann Intern Med"},{"key":"hep31588-bib-0013-20241017","first-page":"517","article-title":"Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","year":"2000","journal-title":"Ann Intern Med"},{"key":"hep31588-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","article-title":"The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","volume":"59","year":"2013","journal-title":"J Hepatol"},{"key":"hep31588-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep31588-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31588-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.dld.2018.10.014","article-title":"Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals","volume":"51","year":"2019","journal-title":"Dig Liver Dis"},{"key":"hep31588-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct\u2010acting antivirals for HCV infection","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31588-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV\u2010associated cirrhosis treated with direct\u2010acting antiviral agents","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"hep31588-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1007\/s10620-019-05604-8","article-title":"Role of liver stiffness measurement in predicting HCC occurrence in direct\u2010acting antivirals setting: a real\u2010life experience","volume":"64","year":"2019","journal-title":"Dig Dis Sci"},{"key":"hep31588-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.dld.2018.02.010","article-title":"Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals","volume":"50","year":"2018","journal-title":"Dig Liver Dis"},{"key":"hep31588-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","year":"2005","journal-title":"Gastroenterology"},{"key":"hep31588-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000445275","article-title":"Treatment of hepatocellular carcinoma","volume":"34","year":"2016","journal-title":"Dig Dis"},{"key":"hep31588-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep31588-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time\u2010dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","year":"2013","journal-title":"Stat Med"},{"key":"hep31588-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep31588-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2893.2006.00811.x","article-title":"Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases","volume":"14","year":"2007","journal-title":"J Viral Hepat"},{"key":"hep31588-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40261-015-0338-y","article-title":"Achieving sustained virological response in hepatitis C reduces the long\u2010term risk of hepatocellular carcinoma: an updated meta\u2010analysis employing relative and absolute outcome measures","volume":"35","year":"2015","journal-title":"Clin Drug Investig"},{"issue":"Suppl 1","key":"hep31588-bib-0030-20241017","first-page":"S60","article-title":"Reversibility of liver fibrosis","volume":"39","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"hep31588-bib-0031-20241017","first-page":"1599","article-title":"Regression of human cirrhosis, morphologic features and the genesis of incomplete septal cirrhosis","volume":"124","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"hep31588-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/hep.28895","article-title":"An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep31588-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB\u20104 scores","volume":"157","year":"2019","journal-title":"Gastroenterology"},{"key":"hep31588-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/hep.29363","article-title":"Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep31588-bib-0035-20241017","first-page":"472","article-title":"Non\u2010invasive prediction of liver\u2010related events in patients with HCV\u2010associated compensated advanced chronic liver disease after oral antivirals","volume":"72","year":"2019","journal-title":"J Hepatol"},{"key":"hep31588-bib-0036-20241017","first-page":"429","article-title":"Predicting liver\u2010related events using transient elastography in chronic hepatitis C patients with sustained virological response","volume":"10","year":"2016","journal-title":"Gut Liv"},{"key":"hep31588-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","year":"2013","journal-title":"J Hepatol"},{"key":"hep31588-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV\u2010induced epigenetic changes associated with liver cancer risk persist after sustained virologic response","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep31588-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/hep.30244","article-title":"Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep31588-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ng0802-339","article-title":"Molecular pathogenesis of human hepatocellular carcinoma","volume":"31","year":"2002","journal-title":"Nat Genet"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31588","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31588","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:04:13Z","timestamp":1729209853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31588","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"2020-07-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}